| 000 | 04869nam a22004695i 4500 | ||
|---|---|---|---|
| 001 | 978-4-431-54412-8 | ||
| 003 | DE-He213 | ||
| 005 | 20140220082524.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 131115s2014 ja | s |||| 0|eng d | ||
| 020 |
_a9784431544128 _9978-4-431-54412-8 |
||
| 024 | 7 |
_a10.1007/978-4-431-54412-8 _2doi |
|
| 050 | 4 | _aRC902-918 | |
| 072 | 7 |
_aMJR _2bicssc |
|
| 072 | 7 |
_aMED055000 _2bisacsh |
|
| 082 | 0 | 4 |
_a616.61 _223 |
| 100 | 1 |
_aNoiri, Eisei. _eeditor. |
|
| 245 | 1 | 4 |
_aThe Concise Manual of Apheresis Therapy _h[electronic resource] / _cedited by Eisei Noiri, Norio Hanafusa. |
| 264 | 1 |
_aTokyo : _bSpringer Japan : _bImprint: Springer, _c2014. |
|
| 300 |
_aXXVII, 418 p. 46 illus., 39 illus. in color. _bonline resource. |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 505 | 0 | _aPart 1. Principles and Technologies -- Chapter 1. Theoretical background of Apheresis Therapy - Norio Hanafusa -- Chapter 2. Methods to Remove Pathogens - Tamami Tanaka -- Chapter 3. Decision to Prescribe PE, DFPP, or PA- Rei Isshiki -- Chapter 4. Plasma Exchange - Daisuke Katagiri -- Chapter 5. Double Filtration Plasmapheresis - Daisuke Katagri -- Chapter 6. Plasma Adsorption- Yasuyuki Watanabe -- Chapter 7. Cryofiltration - Daisuke Katagiri -- Chapter 8. Double Filtration Plasmapheresis Thermo-mode (DF Thermo)- Mizuki Yamano -- Chapter 9. Plasma Diafiltration - Hajime Nakae -- Chapter 10. Direct Plasma Adsorption - Mayumi Miwa -- Chapter 11. Cytapheresis - Yuki Itoh -- Chapter 12. Cell-free and Concentrated Ascites Reinfusion Therapy - Norio Hanafusa -- Part 2. Therapeutic Details -- Chapter 13. Choice of Apheresis Therapy- Eisei Noiri -- Chapter 14. Determination of Dosage and Frequency of Therapy- Norio Hanafusa -- Chapter 15. Vascular Access- Koji Okamoto -- Chapter 16. Anticoagulants - Tetsushi Yamashita -- Part 3. Complications -- Chapter 17. Hypotension - Tsuyoshi Inoue -- Chapter 18. Bleeding Complications and Reduction of Coagulation Factors- Norio Hanafusa -- Chapter 19. Allergies - Motonobu Nakamura -- Chapter 20. Electrolytes Disorders - Motonobu Nakamura -- Chapter 21. Avoiding Complications during Apheresis - Tetsushi Yamashita -- Chapter 22. Infections - Osamu Yamazaki -- Part 4. Autoimmune Disorders -- Chapter 23. Neurological Diseases- Masao Iwagami -- Chapter 24. Dermatological Disorders- Masao Iwagami -- Chapter 25. Kidney Diseases- Masao Iwagami -- Chapter 26. Rheumatoid Arthritis and Collagen Diseases - Hiroko Kanda -- Chapter 27. Blood type incompatible pregnancies - Norio Hanafusa -- Chapter 28. Multiple Myeloma - Tsuyoshi Inoue -- Chapter 29. Dilated Cardiomyopathy - Yoshifumi Hamasaki -- Part 5. Pathogens with Large Molecular Weight.- Chapter 30. Low Density Lipoprotein Apheresis - Kenjiro Honda -- Chapter 31. Endotoxin Adsorption Therapy - Kent Doi -- Part 6. Diseases Necessary to Supply Coagulation Factors -- Chapter 32. Liver Diseases - Kent Doi.- Chapter 33. Thrombotic Thrombocytopenic Purpura and Thrombotic Microangiopathy - Kenjiro Honda.- Chapter 34. Inflammatory Bowel Diseases - Tsuyoshi Inoue.- Chapter 35. Hepatitis C Virus Infection - Shi Lu.- Chapter 36. Drug Intoxications - Motonobu Nakamura -- Chapter 37. Living Related Kidney Transplantation - Hiroo Kawarazaki -- Chapter 38. Peripheral Blood Stem Cell Transplantation- Naoko Watanabe-Okochi -- Part 7. Pediatric Apheresis -- Chapter 39. Apheresis in Children - Motoshi Hattori. | |
| 520 | _aThis pocket-sized manual serves as a concise and ideal reference work for therapeutic approaches using apheresis. Covering both basic theory and clinical details to facilitate improved treatment and patient outcomes, the text considers a variety of diseases, including myasthenia gravis, multiple sclerosis, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, nephrotic syndrome, TTP/TMA, dilated cardiomyopathy, and many other conditions. The book also reviews the growing trend toward adopting this unique therapy for a wide range of health management issues such as morbid obesity and/or type 2 diabetes, and for lowering LDL-cholesterol (cholesterol apheresis) in patients unresponsive to medication or lifestyle modification. | ||
| 650 | 0 | _aMedicine. | |
| 650 | 0 | _aInternal medicine. | |
| 650 | 0 | _aNephrology. | |
| 650 | 0 | _aBiomedical engineering. | |
| 650 | 1 | 4 | _aMedicine & Public Health. |
| 650 | 2 | 4 | _aNephrology. |
| 650 | 2 | 4 | _aInternal Medicine. |
| 650 | 2 | 4 | _aBiomedical Engineering. |
| 700 | 1 |
_aHanafusa, Norio. _eeditor. |
|
| 710 | 2 | _aSpringerLink (Online service) | |
| 773 | 0 | _tSpringer eBooks | |
| 776 | 0 | 8 |
_iPrinted edition: _z9784431544111 |
| 856 | 4 | 0 | _uhttp://dx.doi.org/10.1007/978-4-431-54412-8 |
| 912 | _aZDB-2-SME | ||
| 999 |
_c93686 _d93686 |
||